KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Kolinsky, Michael Paul
Gravis, Gwenaelle
Mourey, Loic
Piulats, Josep M.
Sridhar, Srikala S.
Romano, Emanuela
Berry, William R.
Gurney, Howard
Retz, Margitta
Appleman, Leonard Joseph
Boegemann, Martin
De Bono, Johann S.
Joshua, Anthony M.
Emmenegger, Urban
Conter, Henry Jacob
Laguerre, Brigitte
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
机构：
[1] Cross Canc Inst, Edmonton, AB, Canada
[2] CLCC Inst Paoli Calmettes, Paris, France
[3] SIOG, Toulouse, France
[4] Catalan Inst Oncol, Barcelona, Spain
[5] UHN Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Inst Curie, Ctr Canc Immunotherapy, Paris, France
[7] Duke Canc Ctr Cary, Cary, NC USA
[8] Macquarie Univ Hosp, Sydney, NSW, Australia
[9] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany
[10] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[11] Univ Hosp Muenster, Munster, Germany
[12] Royal Marsden Hosp, London, England
[13] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia
[14] Sunnybrook Res Inst, Toronto, ON, Canada
[15] Univ Western Ontario, Brampton, ON, Canada
[16] Ctr Eugene Marquis, Rennes, France
[17] Merck & Co Inc, Kenilworth, NJ USA
[18] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
103
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
    Yu, Evan Y.
    Piulats Rodriguez, Jose Maria M.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Arranz Arija, Jose Angel
    Oudard, Stephane
    Fong, Peter C. C.
    Kolinsky, Michael Paul
    Augustin, Marinela
    Todenhofer, Tilman
    Kam, Audrey E.
    Gurney, Howard
    Tafreshi, Ali
    Retz, Margitta
    Berry, William R.
    Mar, Nataliya
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.
    Ferrario, Cristiano
    Piulats, Josep M.
    Linch, Mark David
    Stoeckle, Michael
    Laguerre, Brigitte
    Arranz, Jose A.
    Todenhofer, Tilman
    Fong, Peter C. C.
    Berry, William R.
    Emmenegger, Urban
    Mourey, Loic
    Mar, Nataliya
    Appleman, Leonard Joseph
    Joshua, Anthony M.
    Conter, Henry Jacob
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    YuJewish, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [23] Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
    Moses, Marcus Marie
    Ledet, Elisa
    Manogue, Charlotte
    Lewis, Brian E.
    Barata, Pedro C.
    Sartor, A. Oliver
    Layton, Jodi Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [24] Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.
    Fong, Peter C. C.
    Kwiatkowski, Mariusz
    Mosca, Alessandra
    Valderrama, Begona Perez
    Huang, Yi-Hsiu
    Zedan, Ahmed H.
    Kuc, Kamil
    Wiechno, Pawel
    Laguerre, Brigitte
    Gonzalez-Billalabeitia, Enrique
    Osipov, Mikhail
    Dede, Didem Sener
    Goh, Jeffrey
    Daugaard, Gedske
    Zhu, Pengfei
    Imai, Kentaro
    Liu, Yingjie
    Arija, Jose Angel Arranz
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 149 - 149
  • [25] KEYNOTE-365 COHORT D: PEMBROLIZUMAB PLUS ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Piulats, Josep
    Ferrario, Cristiano
    Linch, Mark
    Stoeckle, Michael
    Laguerre, Brigitte
    Arranz, Jose
    Todenhoefer, Tilman
    Fong, Peter
    Berry, William
    Emmenegger, Urban
    Mourey, Loic
    Mar, Nataliya
    Appleman, Leonard
    Joshua, Anthony
    Conter, Henry
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A378 - A378
  • [26] Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Linch, M.
    Ferrario, C.
    Stoeckle, M.
    Laguerre, B.
    Arija, J. A. Arranz
    Todenhofer, T.
    Fong, P. C.
    Rodriguez, J. M. Piulats
    Berry, W.
    Emmenegger, U.
    Mourey, L.
    Mar, N.
    Appleman, L. J.
    Joshua, A.
    Conter, H. J.
    Li, X. T.
    Schloss, C.
    Poehlein, C. H.
    de Bono, J. S.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1178 - S1178
  • [27] PEMBROLIZUMAB (PEMBRO) PLUS OLAPARIB IN PATIENTS WITH DOCETAXEL-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): UPDATED RESULTS FROM KEYNOTE-365 COHORT A WITH A MINIMUM OF 11 MONTHS OF FOLLOW-UP FOR ALL PATIENTS
    Nordquist, Luke T.
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Fong, Peter C. C.
    Todenhoefer, Tilman
    Laguerre, Brigitte
    Arranz Arija, Jose Angel
    Oudard, Stephane
    Massard, Christophe
    Stoeckle, Michael
    Carles, Joan
    Kolinsky, Michael Paul
    Augustin, Marinela
    Gurney, Howard
    Tafreshi, Ali
    Li, Xin Tong
    Poehlein, Christian Heinrich
    Schloss, Charles
    de Bono, Johann S.
    JOURNAL OF UROLOGY, 2021, 206 : E417 - E417
  • [28] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [29] KEYNOTE-365 Cohort B: Pembrolizumab Plus Docetaxel and Prednisone in Abiraterone or Enzalutamide-Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer-New Data After an Additional 1 Year of Follow-Up
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 8 - 9
  • [30] Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients
    Yu, E.
    Piulats, J. M.
    Gravis, G.
    Fong, P. C. C.
    Todenhoefer, T.
    Laguerre, B.
    Arranz Arija, J. A.
    Oudard, S.
    Massard, C.
    Stoeckle, M.
    Nordquist, L. T.
    Carles, J.
    Kolinsky, M. P.
    Augustin, M.
    Gurney, H.
    Tafreshi, A.
    Li, X. T.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S652 - S653
12345